CNTN4 as a novel target for solid cancer with antibody-drug conjugate

被引：0
|
作者：
Cha, Mi Young
Kim, Hyunuk
Byun, Seungmin
Ha, Youngeun
Park, Kitae
Yu, Hyunkyung
Jeon, Bu-Nam
Kim, Mira
Moon, Soojung
Park, Kyung Mi
Park, Hansoo
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-740
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
740
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Antibody-drug conjugate and novel therapy in lung cancer
    Cho, B.
    ANNALS OF ONCOLOGY, 2024, 35 : S1310 - S1311
  • [2] Developing a novel doppel-targeting antibody-drug conjugate (ADC) for solid cancer
    Lee, Ha Kyeong
    Kim, Byoungmo
    Kweon, Seho
    Choi, Jeong Uk
    Kim, Sang Yoon
    Byun, Youngro
    CANCER RESEARCH, 2023, 83 (07)
  • [3] Development of anti-APP antibody targeting APP/CNTN4 axis as a novel cancer immunotherapy
    Cha, Mi Young
    Ha, Youngeun
    Jeon, Bu-Nam
    Kim, Hyunuk
    Kim, Yunyeon
    Lee, Jiyeong
    Kim, Han-Sol
    Jeong, A-Reum
    Yu, Hyunkyung
    Park, Kyung Mi
    Park, Hansoo
    CANCER RESEARCH, 2023, 83 (07)
  • [4] Antibody-drug conjugate for ovarian cancer
    Collingridge, David
    LANCET ONCOLOGY, 2020, 21 (07): : 886 - 886
  • [5] Novel targets for antibody-drug conjugate therapy
    Grandi, A. G.
    Campagnoli, S. C.
    Parri, M. P.
    De Camilli, E. D. C.
    Jin, B. J.
    Sarmientos, P. S.
    Grandi, G. G.
    Terracciano, L. T.
    Pileri, P. P.
    Viale, G. V.
    Grifantini, R.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 41 - 41
  • [6] An amino acid transporter subunit as an antibody-drug conjugate target in colorectal cancer
    Montero, Juan Carlos
    del Carmen, Sofia
    Abad, Mar
    Sayagues, Jose M.
    Barbachano, Antonio
    Fernandez-Barral, Asuncion
    Munoz, Alberto
    Pandiella, Atanasio
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2023, 42 (01)
  • [7] Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)
    Goldenberg, David M.
    Cardillo, Thomas M.
    Govindan, Serengulam V.
    Rossi, Edmund A.
    Sharkey, Robert M.
    ONCOTARGET, 2015, 6 (26) : 22496 - 22512
  • [8] Folate receptor alpha for cancer therapy: an antibody and antibody-drug conjugate target coming of age
    Liu, Yi
    Chen, Xinyi
    Evan, Theodore
    Esapa, Benjamina
    Chenoweth, Alicia
    Cheung, Anthony
    Karagiannis, Sophia N.
    MABS, 2025, 17 (01)
  • [9] Lineage plasticity as a determinant of antibody-drug conjugate target expression in urothelial bladder cancer
    Luo, Jiaqian
    Gao, Sizhi P.
    Kuo, Fengshen
    Ozcan, Gamze Gokturk
    Basar, Merve
    Koll, Florestan
    Tallman, Jacob E.
    Alam, Syed M.
    Chu, Carissa E.
    Chen, Ziyu
    Pietzak, Eugene J.
    Iyer, Gopakumar
    Rosenberg, Jonathan E.
    Solit, David B.
    Al-Ahmadie, Hikmat
    CANCER RESEARCH, 2024, 84 (06)
  • [10] Orexin 2 receptor as a potential target for immunotoxin and antibody-drug conjugate cancer therapy
    Kishida, Masato
    Ishige, Kazunori
    Horibe, Tomohisa
    Tada, Noriko
    Koibuchi, Nobutaka
    Shoda, Junichi
    Kita, Kiyoshi
    Kawakami, Koji
    ONCOLOGY LETTERS, 2012, 3 (03) : 525 - 529
12345